Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF)
The pharmaceutical group announced on 27 July that it has commenced its phase I clinical trial for lead drug candidate, OCT461201, marking the administration of the first human dose.
Appiah describes the news as a "major achievement" for Oxford Cannabinoid Technologies, highlighting its transformation from a development company into being a clinical company He also gives an overview of other recent news from the business. For more details, read Daniel's full report by clicking the link provided.